|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 118.40 EUR | -0.38% |
|
-1.86% | -15.37% |
| 12-11 | Merck KGaA's SpringWorks Gets UK Clearance for Plexiform Neurofibromas Therapy | MT |
| 12-11 | UK's MHRA approves mirdametinib to treat plexiform neurofibromas | RE |
Main competitors
| Dividend Yield (Y) | Dividend Yield (Y+1) | P/E (Y) | Price to Book (Y) | EV / Sales (Y) | EV / EBITDA (Y) | EV / EBIT (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|
 | 1.95% | 2.06% | 17.91x | 1.6x | 2.8x | 9.83x | 15.31x | 60.15B | |
| 2.35% | 2.38% | 24.12x | 1.53x | 2.34x | 10.4x | 13.98x | 8.58B | |
| -.--% | 0.08% | 58.61x | 14.44x | 14.25x | 43.6x | 46.98x | 7.06B | |
| 0.42% | 0.43% | 72.18x | 4.25x | 3.85x | 44x | 68.24x | 5.91B | |
| -.--% | -.--% | 20.2x | -222.25x | 3.65x | 10.56x | 11x | 4.44B | |
| 0.75% | 0.96% | 35.16x | 3.26x | 5.97x | 19.69x | 33.65x | 2.84B | |
| 2.62% | 2.79% | 17.18x | 0.93x | - | - | - | 1.22B | |
| 0.96% | - | 13.63x | 1.87x | - | - | - | 1.16B | |
| Average | 1.13% | 1.24% | 32.37x | -24.30x | 5.48x | 23.01x | 31.53x | 11.42B | |
| Weighted average by Cap. | 1.6% | 1.7% | 25.73x | -8.07x | 3.88x | 15.19x | 21.58x |
- Stock Market
- Equities
- MRK Stock
- Sector Merck KGaA
- Sector dividends
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition